Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Centessa Pharmaceuticals PLC ADR

CNTA
Current price
17.84 USD +0.53 USD (+3.06%)
Last closed 16.92 USD
ISIN US1523091007
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 2 208 403 712 USD
Yield for 12 month +139.14 %
1Y
3Y
5Y
10Y
15Y
CNTA
21.11.2021 - 28.11.2021

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom. Address: 1 Ashley Road, Altrincham, United Kingdom, WA14 2DT

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

28.57 USD

P/E ratio

Dividend Yield

Current Year

+6 853 000 USD

Last Year

Current Quarter

Last Quarter

Current Year

+6 853 000 USD

Last Year

-130 919 USD

Current Quarter

-236 264 USD

Last Quarter

-236 264 USD

Key Figures CNTA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -161 299 008 USD
Operating Margin TTM -2 358.87 %
PE Ratio
Return On Assets TTM -20.47 %
PEG Ratio
Return On Equity TTM -42.52 %
Wall Street Target Price 28.57 USD
Revenue TTM 6 853 000 USD
Book Value 4.29 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -1.52 USD
Diluted Eps TTM -1.52 USD
Most Recent Quarter III 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CNTA

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History CNTA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation CNTA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 258.96
Price Sales TTM 322.25
Enterprise Value EBITDA 1.12
Price Book MRQ 4.42

Financials CNTA

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CNTA

For 52 weeks

6.65 USD 18.97 USD
50 Day MA 16.47 USD
Shares Short Prior Month 2 438 816
200 Day MA 12.38 USD
Short Ratio 5.32
Shares Short 3 345 785
Short Percent 3.12 %